STAT-5 is activated constitutively in T cells, B cells and monocytes from patients with primary Sjögren's syndrome

Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)

(2014) P M Meiners et al.   ANNALS OF THE RHEUMATIC DISEASES

The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels

(2014) Pia Isomäki et al.   RHEUMATOLOGY

Sjögren's Syndrome

(2013) Clio P. Mavragani et al.   Annual Review of Pathology-Mechanisms of Disease

Essentials of Th17 cell commitment and plasticity

(2013) P. Muranski et al.   BLOOD

JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia

(2013) W. Warsch et al.   BLOOD

Advances in understanding the pathogenesis of primary Sjögren's syndrome

(2013) Gaëtane Nocturne et al.   Nature Reviews Rheumatology

Clinical features distinguishing lymphoma development in primary Sjögren's syndrome—A retrospective cohort study

(2013) Anna P. Risselada et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

The role of STAT5 in lymphocyte development and transformation

(2012) Lynn M Heltemes-Harris et al.   CURRENT OPINION IN IMMUNOLOGY

TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjogren's syndrome

(2012) Seung-Ki Kwok et al.   ARTHRITIS RESEARCH & THERAPY

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome

(2011) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndrome

(2011) Francesco Ciccia et al.   ANNALS OF THE RHEUMATIC DISEASES

Multidimensional Single Cell Based STAT Phosphorylation Profiling Identifies a Novel Biosignature for Evaluation of Systemic Lupus Erythematosus Activity

(2011) Xinfang Huang et al.   PLoS One

Effectiveness of rituximab treatment in primary Sjögren's syndrome: A randomized, double-blind, placebo-controlled trial

(2010) J. M. Meijer et al.   ARTHRITIS AND RHEUMATISM

Pathogenesis of Sjögrenʼs syndrome and therapeutic consequences

(2010) Xavier Mariette et al.   CURRENT OPINION IN RHEUMATOLOGY

STAT4 is a confirmed genetic risk factor for Sjögren's syndrome and could be involved in type 1 interferon pathway signaling

(2010) N Gestermann et al.   GENES AND IMMUNITY

Activation of the type I interferon pathway in primary Sjogren’s syndrome

(2010) Clio P. Mavragani et al.   JOURNAL OF AUTOIMMUNITY

Influence of STAT4 Polymorphism in Primary Sjogren's Syndrome

(2010) R. J. PALOMINO-MORALES et al.   JOURNAL OF RHEUMATOLOGY

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

(2009) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

The numbers of Foxp3 + Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjögren's syndrome

(2009) M. Sarigul et al.   LUPUS

Hematologic Manifestations and Predictors of Lymphoma Development in Primary Sjögren Syndrome

(2009) Evangelia Baimpa et al.   MEDICINE

Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome

(2008) G Nordmark et al.   GENES AND IMMUNITY

Variant form of STAT4 is associated with primary Sjögren's syndrome

(2008) B D Korman et al.   GENES AND IMMUNITY

Linked T Cell Receptor and Cytokine Signaling Govern the Development of the Regulatory T Cell Repertoire

(2008) Matthew A. Burchill et al.   IMMUNITY

Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T‐cell subsets and inflammatory cytokines

(2008) P. Szodoray et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Constitutive STAT3 activation in peripheral CD3+cells from patients with primary Sjögren's syndrome

(2008) H. L. Ramos et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY